3.5 | | PAM16 | 'sebaceous of Jadassohn nevus' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
3.2 | | PAM16 | 'actinic keratosis' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
3.2 | | PAM16 | 'squamous cell carcinoma' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-3 | | PAM16 | 'P-bodies (cytosolic RNP granules)' vs 'pre-sorted fraction' | fraction | RNA-Seq of purified P-bodies from HEK293 cells |
-2.9 | | PAM16 | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.3 | | PAM16 | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.9 | | PAM16 | 'COVID-19' vs 'normal' in 'colon' | disease, organism part | Lung and colon transcriptome profiling of fatal COVID-19 cases |
1.8 | | PAM16 | '6 hour' vs '0 hour' in 'MCF-10A-H1047R' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1.8 | | PAM16 | 'esophageal adenocarcinoma' vs 'normal' | disease, disease staging | Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's |
-1.7 | | PAM16 | 'correction to MCT8[wt]' vs 'wild type genotype' in 'derived neural cell; T3; 100 nanomolar' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
-1.7 | | PAM16 | 'doxycycline; 0.5 microgram per milliliter; Day 4 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
-1.5 | | PAM16 | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.4 | | PAM16 | 'MEF2D-HNFNPUL1 knockdown by siRNA' vs 'luciferase siRNA' | RNA interference | RNA-seq for gene expression changes upon silencing MEF2D-fusion in a MEF2D-HNRNPUL1 fusion-expressing Kasumi-7 cell line |
-1.4 | | PAM16 | ' neural stem cell' vs 'induced pluripotent stem cell' in 'Ataxia-telangiectasia' | cell type, disease | Human iPSC-Derived Cerebellar Neurons from a Patient with Ataxia-Telangiectasia Reveal Disrupted Gene Regulatory Networks |
-1.3 | | PAM16 | 'progenitor cell of endocrine pancreas' vs 'definitive endoderm cell' in 'GATA6 R456C/+; Patient A" | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
-1.3 | | PAM16 | 'CD3/CD28 beads' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
-1.3 | | PAM16 | 'MCT8[P321L]' vs 'wild type genotype' in 'derived neural cell; T3; 100 nanomolar' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
1.3 | | PAM16 | 'SNCA overexpression' vs 'wild type genotype' | genotype | RNA-seq of human midbrain organoid models of Parkinson's Disease |
-1.2 | | PAM16 | 'induced MCT8 mutation' vs 'wild type genotype' in 'derived neural cell; T3; 100 nanomolar' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
1.2 | | PAM16 | '6 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-1.2 | | PAM16 | 'T3; 100 nanomolar' vs 'none' in 'derived neural cell; correction to MCT8[wt]' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
-1.2 | | PAM16 | '11 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
-1.2 | | PAM16 | 'doxycycline; 0.5 microgram per milliliter; Day 3 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
-1.2 | | PAM16 | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
1.1 | | PAM16 | 'high LDL' vs 'control' | growth condition | RNA-seq of human cardiovascular endothelial cell line HUVEC, treated with different media |
1.1 | | PAM16 | 'KLF17 overexpression' at '24 day' vs 'wild type' at '0 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
-1.1 | | PAM16 | 'expression of estrogen receptor beta fused to N terminus tandem affinity purification tag' vs 'expression of estrogen receptor alpha fused to C terminus tandem affinity purification tag' | genotype | The nuclear receptor ERbeta engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading. Part 4 |
-1 | | PAM16 | 'injected in NSG mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
1 | | PAM16 | 'KLF5 knockdown by siRNA' vs 'scrambled siRNA' | RNA interference | RNA-seq of OE19 cells treated with siNT or siKLF5 for 72 hours |
1 | | PAM16 | 'pBABE-puro-H-RasG12V; senescent' vs 'control; proliferative' | genotype, phenotype | Transcription profiling by high throughput sequencing of proliferative and Ras-induced senescent human primary fibroblasts |
1 | | PAM16 | 'SPRY1 knockdown by siRNA' vs 'none' | RNA interference | Loss of Spry1 reduces growth of BRAFV600E-mutant cutaneous melanoma and improves response to targeted therapy |
1 | | PAM16 | 'induced into senescence; 5-aza-2-deoxycytidine' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
